Literature DB >> 19335222

Chronic recurrent multifocal osteomyelitis mimicked in childhood hypophosphatasia.

Michael P Whyte1, Deborah Wenkert, William H McAlister, M Zulf Mughal, Anthony J Freemont, Richard Whitehouse, Eileen M Baildam, Stephen P Coburn, Lawrence M Ryan, Steven Mumm.   

Abstract

Hypophosphatasia (HPP) is the inborn error of metabolism characterized by low serum alkaline phosphatase (ALP) activity caused by inactivating mutations within TNSALP, the gene that encodes the "tissue-nonspecific" isoenzyme of ALP (TNSALP). In HPP, extracellular accumulation of inorganic pyrophosphate, a TNSALP substrate, inhibits hydroxyapatite crystal growth leading to rickets or osteomalacia. Chronic recurrent multifocal osteomyelitis (CRMO) is the pediatric syndrome of periarticular pain and radiographic changes resembling infectious osteomyelitis but without lesional pathogens. Some consider CRMO to be an autoinflammatory disease. An unrelated boy and girl with the childhood form of HPP suffered chronic, multifocal, periarticular pain, and soft tissue swelling. To investigate this unusual complication, we evaluated their cumulative clinical, biochemical, radiological, and histopathological findings and performed mutation analysis of their TNSALP alleles. The earliest radiographic disturbances were typical of childhood HPP. Subsequently, changes consistent with CRMO developed at sites where there was pain, including lucencies, osteosclerosis, and marked expansion of the underlying metaphyses. Bone marrow edema was shown by MRI. Biopsies of affected bone showed nonspecific histopathological findings and no pathogens. The boy was heterozygous (c.1133A>T, p.D378V) and the girl compound heterozygous (c.350A>G, p.Y117C, c.400_401AC>CA, p.T134H) for different TNSALP missense mutations. Nonsteroidal anti-inflammatory drugs diminished their pain, which improved or resolved at maturity. HPP should be considered when CRMO is a diagnostic possibility. Metaphyseal radiographic changes and marrow edema associated with periarticular bone pain and soft tissue swelling suggestive of osteomyelitis can complicate childhood HPP.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19335222     DOI: 10.1359/jbmr.090308

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  27 in total

Review 1.  Clinical management of hypophosphatasia.

Authors:  Nick Bishop
Journal:  Clin Cases Miner Bone Metab       Date:  2015-10-26

2.  Clinical utility gene card for: hypophosphatasia - update 2013.

Authors:  Etienne Mornet; Christine Hofmann; Agnès Bloch-Zupan; Hermann Girschick; Martine Le Merrer
Journal:  Eur J Hum Genet       Date:  2013-08-07       Impact factor: 4.246

3.  Skeletal mineralization defects in adult hypophosphatasia--a clinical and histological analysis.

Authors:  F Barvencik; F Timo Beil; M Gebauer; B Busse; T Koehne; S Seitz; J Zustin; P Pogoda; T Schinke; M Amling
Journal:  Osteoporos Int       Date:  2011-01-26       Impact factor: 4.507

Review 4.  Transient osteoporosis of the hip: review of the literature.

Authors:  K Asadipooya; L Graves; L W Greene
Journal:  Osteoporos Int       Date:  2017-03-17       Impact factor: 4.507

5.  Whole-body MRI in the childhood form of hypophosphatasia.

Authors:  C Beck; H Morbach; C Wirth; M Beer; H J Girschick
Journal:  Rheumatol Int       Date:  2010-04-10       Impact factor: 2.631

Review 6.  Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment.

Authors:  Michael P Whyte
Journal:  Nat Rev Endocrinol       Date:  2016-02-19       Impact factor: 43.330

Review 7.  Alkaline phosphatase: a potential biomarker for stroke and implications for treatment.

Authors:  Allison L Brichacek; Candice M Brown
Journal:  Metab Brain Dis       Date:  2018-10-04       Impact factor: 3.584

Review 8.  Hypophosphatasia: Biological and Clinical Aspects, Avenues for Therapy.

Authors:  Jean Pierre Salles
Journal:  Clin Biochem Rev       Date:  2020-02

Review 9.  Chronic recurrent multifocal osteomyelitis.

Authors:  Patrícia Costa-Reis; Kathleen E Sullivan
Journal:  J Clin Immunol       Date:  2013-05-22       Impact factor: 8.317

Review 10.  Hypophosphatasia: an overview of the disease and its treatment.

Authors:  M L Bianchi
Journal:  Osteoporos Int       Date:  2015-08-06       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.